Why Sight Sciences, Inc.’s (SGHT) Stock Is Up 7.06%
As of Wednesday, August 19, Sight Sciences, Inc.’s SGHT share price has surged by 7.06%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Commentary & Analysis
Is Sight Sciences, Inc. (SGHT) Overvalued?
We dive into why Sight Sciences, Inc. (SGHT) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Tudor Pop
Why Sight Sciences, Inc.’s (SGHT) Stock Is Up 5.42%
As of Wednesday, August 12, Sight Sciences, Inc.’s SGHT share price has surged by 5.42%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Sight Sciences, Inc.’s (SGHT) Stock Is Up 19.73%
As of Thursday, August 06, Sight Sciences, Inc.’s SGHT share price has surged by 19.73%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Sight Sciences, Inc.’s (SGHT) Stock Is Up 27.75%
As of Thursday, August 06, Sight Sciences, Inc.’s SGHT share price has surged by 27.75%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | SGHT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $449.0 | $407.7 | 35% |
|
| Shares Out (Mil) | 54.5 | 41.3 | 49% |
|
| Institutional Ownership | 65.7% | 81.4% | 41% |
|
| Float (Mil) | 35.6 | 34.9 | 40% |
|
| Beta | 2.42 | 0.88 | 96% |
|
| Avg Daily Volume (000s) | 352 | 412 | 52% |
|
| Price Change (52-week) |
99.3% | 64.8% | 90% |
|
| Growth | SGHT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.9% | 11.8% | 84% |
|
| Net Income (5yr) | (2.0%) | (6.0%) | 37% |
|
| EPS (5yr) | 27.6% | 10.4% | 78 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.3%) | (16.2%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.127) | ($0.493) | ($0.432) | |
| Month Ago EPS | ($0.160) | ($0.655) | ($0.530) | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.160) | ($0.655) | ($0.530) | |
| Year/Year Chg | 54.9% | (33.1%) | (51.7%) | |
| Financials | SGHT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $83 | $119 | 25% |
|
| Net Income (TTM) (Mil) | ($30) | ($9) | 21% |
|
| EPS (TTM) | ($0.556) | ($0.400) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($23) | ($3) | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($22) | $1 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $31 | $21 | 35% |
|
| Enterprise Value (Q1) (Mil) | $418 | $427 | 33% |
|
| Valuation | SGHT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.40 | 3.06 | 88% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | SGHT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 88.0% | 58.9% | 93% |
|
| Net Margin | (35.7%) | (6.9%) | 14% |
|
| ROA | (26.2%) | (12.7%) | 18% |
|
| ROE | (48.4%) | (13.1%) | 16% |
|
| Liabilities to Assets | 49.6% | 46.0% | 42% |
|
| F-Score | 5 | 4 | 50% |
|
Sight Sciences, Inc. did not pass any screens on 8/20/2026.
